The Danish Protease Inhibitor Study: A randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection

Journal of Infectious Diseases

Volumn 182, Issue 3, 2000, Pages 744-750

  Katzenstein, Terese L ^a   Kirk, Ole ^b   Pedersen, Court ^d   Lundgren, Jens D ^b   Nielsen, Henrik ^e   Obel, Niels ^f   Nielsen, Claus ^c   Mathiesen, Lars R ^b   Gerstoft, Jan ^a  

^a University of Copenhagen   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; NUCLEOSIDE DERIVATIVE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; RITONAVIR; SAQUINAVIR; VIRAL LOAD;

EID: 0033823569     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315746     Document Type: Article

References (33)

1. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
2. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers
3. Changing patterns of mortality across Europe in patients infected with HIV-1
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
6. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
9. A randomized, double blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC versus AZT/3TC/indinavir in antiretroviral naive patients. AVANTI 2
10. A randomised double-bind comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC versus AZT/3TC/nelfinavir in antiretroviral naive patients. AVANTI 3
11. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial
12. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: Protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors
13. The Atlantic Study: A randomized open-label study comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen
14. Ziagen (abacavir, ABC, 1592) combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral therapy-naive subjects (CNA3003)
15. Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy (ART) naive adults at 24 weeks (CNA3005)
16. A phase III multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz + indinavir, versus EFV + zidovudine + lamivudine, versus IND + ZDV + 3TC at 48 weeks
17. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel
18. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
19. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial
20. Development of resistance to zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy
21. Detection of low HIV-1 RNA levels in plasma
22. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy
23. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV RNA at the nadir
24. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE Study)
25. Analysis of HIV-1 clinical trials: Statistical magic?
26. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
27. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
28. Issues in the design of trials of therapies for subjects with human immunodeficiency virus infection that use plasma RNA level as an outcome
29. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
30. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
31. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
32. Alterations in plasma triglyceride levels during treatment with three different protease inhibitor regimens: A randomized study
33. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir